iBio reports IBIO-610 muscle-preservation data from primate study

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. CRWV
2. SPY
3. SLGN
4. MANE
5. ABBV
6. CHRD
7. EVR
8. EYPT
9. SLN
10. MKSI

Go back to iBio reports IBIO-610 muscle-preservation data from primate study

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

October 13, 2026 7:00 AM EDT

 In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone

iBio expects to start first-in-human trials of IBIO-610 in first half of 2027

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate,... More